Scopolamine Market Share

APAC Market Statistics

The market share of scopolamine in Asia Pacific, amongst the market in all the other regions, is projected to be the largest with a share of about 32% by the end of 2036. The growth of the market is attributed to the increasing number of people suffering from ophthalmic disorders and the increasing number of surgeries in the elderly population. The rising application in asthma and smoking cessation is driving the market growth in the coming years. The presence of key players in the region and increasing product launches in the region is anticipated to fuel the market growth. The rising trials for the application of scopolamine in the place of antidepressants or sedatives or hypnotics are driving the market growth. The increasing application in patients with open-angle glaucoma with caution is also expected to boost the market growth. The increased healthcare expenditure, presence of medium and small-sized market players, and increasing medical tourism for the purpose of surgeries in the region are estimated to propel the market growth. According to the World Bank, in China, the share of health expenditure as a percentage of GDP has risen to 5.4% in 2018, up from 4.2% in 2010. 

North American Market Forecast

The North American scopolamine market is estimated to be the second largest, registering a share of about 28% by the end of 2036. The growth of the market can be attributed majorly to the rising research and development to find the benefits of scopolamine in psychological disorders. Many people suffering from psychological stress and anxiety are estimated to have a positive impact on market growth. The increasing number of orthopedic surgeries across the region with growing knee pains and disorders is expected to boost the market growth. The increasing geriatric population undergoing several surgical procedures is estimated to propel the market growth in the coming years. Furthermore, the North American region is anticipated to occupy a notable market share during the forecast period owing to its well-established healthcare and pharmaceutical infrastructure, and the strong presence of crucial market companies. Additionally, a growing number of surgeries performed in the region, an increasing number of travelers, along with a rise in product launches are also anticipated to lead to market growth in the near future. For instance, domestic travel in the U.S. increased by 1.9% in 2018, which is a total of 2.3 billion-person trips, as per the reports of the U.S. Travel Association.

Europe Market Forecast

Further, the market in Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2036. The growth of the market can be attributed to the rising number of treatment trials for depression to treat people suffering from depression. The increasing healthcare expenditure and growing research and development on the antidepressant effect of scopolamine are estimated to hike the growth of the market. Additionally, the market growth is attributed to the increasing applications during surgery to prevent secretions and after surgery to prevent dizziness and nausea. The rising investigation for the application in unipolar and bipolar disorder treatments is propelling the market growth. The rising penetration of e-pharmacy and increasing application in the dilation of the pupil during eye disorders is estimated to hike the growth of the market.